Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Trade Desk
TTD
|
$869M |
| 2 |
10x Genomics
TXG
|
$712M |
| 3 |
Recursion Pharmaceuticals
RXRX
|
$676M |
| 4 |
Snowflake
SNOW
|
$621M |
| 5 |
OTLY
Oatly Group
OTLY
|
$583M |
Top Sells
| 1 |
Alphabet (Google) Class C
GOOG
|
$1.57B |
| 2 |
Amazon
AMZN
|
$1.49B |
| 3 |
Mastercard
MA
|
$663M |
| 4 |
Ferrari
RACE
|
$384M |
| 5 |
Interactive Brokers
IBKR
|
$300M |
Sector Composition
| 1 | Consumer Discretionary | 29.73% |
| 2 | Healthcare | 22.49% |
| 3 | Technology | 18.75% |
| 4 | Communication Services | 13.22% |
| 5 | Financials | 4.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Stratasys
SSYS
$866M
| $23M | 0.01% |
888,352
+742
| +0.1% | +$19.2K |
|
227
StoneCo
STNE
$4.42B
| $22.8M | 0.01% |
339,664
+235,608
| +226% | +$15.8M |
|
228
CEVA Inc
CEVA
$534M
| $22.8M | 0.01% |
481,132
-6,597
| -1% | -$312K |
|
229
Certara
CERT
$1.7B
| $22.3M | 0.01% |
787,464
| – | – |
|
230
American Superconductor
AMSC
$2.19B
| $22.2M | 0.01% |
1,279,400
+117,700
| +10% | +$2.05M |
|
|
NBTX
231
Nanobiotix
NBTX
$411M
| $19.3M | 0.01% |
1,400,000
| – | – |
|
232
Masimo
MASI
$7.77B
| $18.7M | 0.01% |
77,328
+9,230
| +14% | +$2.24M |
|
233
Align Technology
ALGN
$9.76B
| $16.7M | 0.01% |
27,354
-1,992
| -7% | -$1.22M |
|
234
Health Catalyst
HCAT
$232M
| $16.6M | 0.01% |
299,562
+36,732
| +14% | +$2.04M |
|
|
CLLS
235
Cellectis
CLLS
$264M
| $16M | 0.01% |
+1,033,872
| New | +$16M |
|
236
HUTCHMED
HCM
$2.55B
| $14.4M | 0.01% |
367,258
+44,105
| +14% | +$1.73M |
|
237
Invesco Senior Income Trust
VVR
$555M
| $14.3M | 0.01% |
3,195,695
| – | – |
|
|
BNFT
238
DELISTED
Benefitfocus, Inc.
BNFT
| $13.3M | 0.01% |
944,406
-108
| -0% | -$1.52K |
|
239
Cooper Companies
COO
$13.5B
| $13.1M | 0.01% |
132,408
-10,392
| -7% | -$1.03M |
|
240
Visa
V
$681B
| $13.1M | 0.01% |
55,850
-16,487
| -23% | -$3.86M |
|
241
Sherwin-Williams
SHW
$91.2B
| $12.9M | 0.01% |
47,386
-2,507
| -5% | -$683K |
|
|
KDNY
242
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $11.9M | 0.01% |
839,380
-6,105
| -0.7% | -$86.2K |
|
243
Ionis Pharmaceuticals
IONS
$9.46B
| $10.8M | 0.01% |
271,396
+33,437
| +14% | +$1.33M |
|
|
UBX
244
DELISTED
Unity Biotechnology
UBX
| $10.7M | 0.01% |
230,411
-149,890
| -39% | -$6.95M |
|
245
Veeva Systems
VEEV
$44.3B
| $10.7M | 0.01% |
34,283
+4,039
| +13% | +$1.26M |
|
|
NCNA
246
NuCana
NCNA
$5.46M
| $10.1M | ﹤0.01% |
732
| – | – |
|
247
Ascendis Pharma
ASND
$12B
| $9.81M | ﹤0.01% |
74,552
-27,742
| -27% | -$3.65M |
|
248
Verisk Analytics
VRSK
$37.7B
| $9.48M | ﹤0.01% |
54,263
-3,258
| -6% | -$569K |
|
249
British American Tobacco
BTI
$121B
| $8.54M | ﹤0.01% |
217,217
-1,580
| -0.7% | -$62.1K |
|
250
Burford Capital
BUR
$2.91B
| $8.13M | ﹤0.01% |
+790,620
| New | +$8.13M |
|